September 9, 2024 08:58 AM EDTUpdated 03:53 PM

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

Lei Lei Wu

News Reporter

Mid-stage clinical trial results show why Merck and Daiichi Sankyo recently moved an antibody-drug conjugate from their $4 billion partnership into Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Mer­ck, Dai­ichi Sankyo de­tail Phase 2 ADC re­sults in small cell lung can­cer, bis­pe­cif­ic com­bo strat­e­gy

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy